Progyny Inc. (PGNY) Next Earnings Date & Expected ±7.3% Move

PGNY scores 78 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

• Fundamental Cash Engine (17/20): Per the RQD rating, this pillar reflects ROIC of 16.7% and an FCF yield of 8.8%. For an investor, this is the strongest pillar and suggests the business converts capital into cash efficiently relative to its market value.
• Whale 13F Flow (15/20): Institutional accumulation and options positioning. The source provides no 13F holder detail (see Analyst View section), so the score cannot be traced to specific holdings in the supplied data.
• Insider Conviction (16/20): SEC Form 4 and Congressional PTR cluster flow. The supplied holders section contains no insider transactions, so this score cannot be independently verified from the provided sources.
• Macro Regime Fit (15/20): Beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level volatility relative to the broader market; an investor should weigh this against the 52-week range of $16.1 – $33.06.
• Forensic Balance Sheet (15/20): Altman Z-Score of 8.84, Piotroski F-Score of 7/9, and Debt/Equity of 0.5. These point to a financially sound balance sheet by the cited metrics.

Investor implications: The valuation tradeoff is material. At a P/E (TTM) of 37.2 and forward P/E of 34.6, the stock prices in substantial future earnings growth relative to the trailing EPS of 0.76. Upside drivers cited in the data include strong cash conversion and balance sheet metrics; the primary valuation risk is that a premium multiple leaves limited margin for execution misses. The RQD rating is a composite framework score and does not constitute a recommendation.

Progyny Inc. Is a NASDAQ-listed company in the Health Care sector, operating in the Misc Health and Biotechnology Services industry. The company generated FY 2025 revenue of $1.29B, indicating scale in its reported operations.

Revenue rose from $1.09B (FY 2023) to $1.29B (FY 2025) and operating income rose from $62.2M to $85.3M over the same span. Per the market data, gross margin is 23.6%, operating margin 6.6%, and net margin 4.5%. ROIC is 16.7%, and the forensic balance sheet pillar cites an Altman Z-Score of 8.84 and a Piotroski F-Score of 7/9. Cash declined from $162.3M (FY 2024) to $112.

• 🐂 Primary Bull Case: Strong cash engine with 16.7% ROIC and 8.8% FCF yield, supported by an 8.84 Altman Z-Score. With Fundamental Cash Engine at 17/20 (ROIC 16.7%, FCF yield 8.80%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $16.10 – $33.06 52-week range.
• 🐻 Primary Bear Case: A 37.2 trailing P/E and declining cash balance leave little valuation margin if execution slips. Investors must weigh 37.2x trailing P/E and 20.5x EV/EBITDA against 6.6% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the supplied data. Investors should note that the absence of graph links means ripple effects are not quantified here. Sector context is limited to the Health Care classification and the beta of 1.0.

• Key Question #1: Why did cash decline from $162.3M to $112.2M between FY 2024 and FY 2025 despite rising FCF, and what was the use of capital?
• Key Question #2: What drives the 37.2 trailing P/E and 34.6 forward P/E, and what earnings trajectory is assumed by the market?
• Key Question #3: How sensitive is PGNY's 23.6% gross margin and 34.6x forward P/E multiple to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?